AZD1402 (Elarekibep) is a novel anticalin with engineered IL-4Rα antagonist binding properties that was under development for inhaled treatment of asthma. Structural similarity to tear-lipocalin is thought to limit immunogenicity risk; however, a range of treatment-emergent hypersensitivity-like adverse events were observed in a clinical study. This study aimed to (i) explore the activation of drug-exposed human T-cells with A...